Table 3 Most active compounds in vitro from the GlaxoSmithKline discontinued drugs compound set
From: Repositioning: the fast track to new anti-malarial medicines?
Compound | Class (therapeutic area) | IC50μM |
|---|---|---|
Piritrexim | Dihydrofolate reductase inhibitor (oncology) | 0.011 ± 0.001 |
SB-435495 | Phospholipase A2-inhibitor (anti-infective/anti-inflammatory) | 1.126 ± 0.146 |
Lurtotecan | Topoisomerase I inhibitor (oncology) | 0.191 ± 0.062 |
GSK202405 | Muscarinic receptor agonist (asthma) | 1.582 ± 0.206 |